Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration

By Bert Oosthuyse, L. Moons, E. Storkebaum, H. Beck, D. Nuyens, K. Brusselmans, J. Dorpe, P. Hellings, M. Gorselink, S. Heymans and 22 more. Nature Genetics, 2001

1,055 citations recorded by the source corpus.

Subfields: Genetics, Neurology

View Paper: https://www.semanticscholar.org/paper/bd2d078100ad7643074e99fc725927e95e3b62e4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Neurology

Citations in the corpus

The blood-brain barrier in health and chronic neurodegenerative disorders. (2008, positive): “It has been suggested that altered expression of JAM-A, in addition to affecting the junctional tightness, may also affect leukocyte trafficking, with implications for immune status within the diseased CNS (Padden et al., 2007).”
Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. (2011, background): “Furthermore, recent studies strongly suggest that some degenerative diseases, such as neuronal degeneration, are due to lower circulation as well as lower VEGF-VEGFR signaling in neuronal cells.(60,61) For the treatment of ischemic heart and brain diseases, pro-angiogenic therapy could be useful bec”
Role of platelet-derived growth factors in physiology and medicine. (2008, positive): “Targeted mutagenesis of the VEGF-A promoter region results in motoneuron death and the development of amyotrophic lateral sclerosis-like disease (Oosthuyse et al. 2001).”
Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. (2003, neutral): “(Oosthuyse et al., 2001; Sondell et al., 1999, 2000).”
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions (2014, background): “These include: endothelial cells of the normal vasculature [218], dendritic cells [219], myeloid cells [220], neurons [221], pericytes [222] and tumour cells [201, 212, 223–228].”
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders (2011, background): “Moreover, mice with a mutation that eliminates hypoxia-responsive induction of the Vegf gene ( Vegf δ/δ mice ) develop late-onset motor neuron degeneratio”
Hypoxia: A key regulator of angiogenesis in cancer (2007, neutral): “Conditional deletion of HRE sites in the VEGF promoter in neural tissue of mice resulted in a gradual decline in motor performance due to degeneration of motor neurons, symptoms similar to that seen in human amyotrophic lateral sclerosis (ALS), suggesting that VEGF might play an important role in th”
The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease (2005, background): “Reduced VEGF-A expression resulting from deletion of the HRE from the VEGF-A promoter predisposes mice to ALS-like motor-neuron degeneration, and mice can be protected against ALS by treatment with VEGF-A [48].”
Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. (2007, positive): “Conversely, low VEGF-A levels have been linked to motor neuron degeneration in both animal models and human disease.(6,7) Taken together, these results suggest an important role for VEGF-A in neuronal development and maintenance within the central nervous system.”
Innate immunity: the missing link in neuroprotection and neurodegeneration? (2002, background): “Mutant mice developed profound progressive motor deficits between five and seven months of age, which were accompanied by the classical hallmarks of ALS: accumulation of neurofilament proteins in spinal cord and brainstem motor neurons, selective degeneration of motor axons, and denervation-induced ”